Kamada Ltd (KMDA) is a publicly traded Healthcare sector company. As of May 21, 2026, KMDA trades at $7.87 with a market cap of $451.68M and a P/E ratio of 0.00. KMDA moved +3.62% today. Year to date, KMDA is +8.70%; over the trailing twelve months it is +14.56%. Its 52-week range spans $5.17 to $9.35. Analyst consensus is buy with an average price target of $13.00. Rallies surfaces KMDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kamada Q1 Revenue Hits $45.2M, Affirms $200M–$205M 2026 Guidance: First quarter revenue climbed 3% year-over-year to $45.2 million with adjusted EBITDA of $11.6 million delivering a 26% margin and net income of $4.1 million, up 4%. Kamada reaffirmed its 2026 guidance of $200–$205 million in revenues and $50–$53 million of adjusted EBITDA.
| Metric | Value |
|---|---|
| Price | $7.87 |
| Market Cap | $451.68M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.25% |
| 52-Week High | $9.35 |
| 52-Week Low | $5.17 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover KMDA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.00.